Clinical Effect of Daglizin on Patients with Heart Failure after Acute Myo-cardial Infarction
Objective To investigate the effect of daglipzin on patients with heart failure after acute myocardial in-farction.Methods A total of 136 patients with primary acute myocardial infarction and heart failure were selected from Janu-ary 2022 to June 2023.Randomly divided into observation group(59 cases)and control group(77 cases).The observation group was treated with standard anti-heart failure regimen plus daglipzin,and the control group was treated with standard anti-heart failure regimen.The changes of N-terminal B-type natriuretic peptide precursor(NT-proBNP),left ventricular end-diastolic inner diameter(LVEDD),left ventricular ejection fraction(LVEF)and other cardiac color ultrasound indicators were detected during hospitalization and 1 year after discharge in the 2 groups,and the incidence of major adverse cardiovascu-lar events(MACE)and adverse reactions during the 6-min walking test and follow-up period were compared.Results After treatment,NT-proBNP and LVEDD in observation group were lower than those in control group,and LVEF was higher than those in control group(P＜0.05,P＜0.01).After treatment,NYHA grade of cardiac function in observation group was sig-nificantly improved compared with control group(P＜0.05).After treatment,the 6-min walking test distance of observation group was longer than that of control group(P＜0.05).Observation group,the incidence of MACE[3.39%(2/59)]is lower than the control group[14.29%(11/77)],the difference was statistically significant(P＜0.05).There was no sig-nificant difference in the incidence of adverse reactions between the two groups(P＞0.05).Conclusion Daglizin can im-prove the cardiac function and left ventricular remodeling in patients with acute myocardial infarction,and reduce the inci-dence of MACE.
国家科技期刊平台
NSTL
万方数据
